| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.30.1077 |
| P698 | PubMed publication ID | 21098318 |
| P50 | author | Víctor Moreno | Q40183186 |
| Gabriel Capella | Q42808840 | ||
| Corrie Marijnen | Q57613319 | ||
| Peter Kuppen | Q58280273 | ||
| Ramon Salazar | Q59123208 | ||
| Annuska Glas | Q71239676 | ||
| Adriana Lopez-Doriga | Q116793811 | ||
| Paul Roepman | Q116793816 | ||
| P2093 | author name string | Hans Morreau | |
| David Kerr | |||
| Cristina Santos | |||
| Laura J Van't Veer | |||
| Iris Simon | |||
| Christa Dreezen | |||
| Johan Westerga | |||
| Cornelis van de Velde | |||
| Sjoerd Bruin | |||
| Rob Tollenaar | |||
| Loes Van Velthuysen | |||
| P2860 | cites work | RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities | Q24651467 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 17-24 | |
| P577 | publication date | 2010-11-22 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer | |
| P478 | volume | 29 |
| Q56675475 | 'Toxgnostics': an unmet need in cancer medicine |
| Q30239808 | 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications |
| Q37082526 | A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI. |
| Q34539848 | A 19-Gene expression signature as a predictor of survival in colorectal cancer |
| Q34227755 | A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer |
| Q41159551 | A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction |
| Q37413869 | A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers |
| Q37040673 | A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients |
| Q49202365 | A gene expression-based risk model reveals prognosis of gastric cancer |
| Q33688589 | A long non-coding RNA signature to improve prognosis prediction of colorectal cancer |
| Q36109706 | A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients |
| Q38647048 | A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer |
| Q49607836 | A robust gene signature for the prediction of early relapse in stage I-III colon cancer |
| Q36494964 | A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency |
| Q47103045 | A seven-gene signature predicts overall survival of patients with colorectal cancer |
| Q39454414 | A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. |
| Q36315165 | AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? |
| Q37451822 | AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. |
| Q37711623 | Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer |
| Q92012575 | Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study |
| Q37956401 | Adjuvant therapy for early colon cancer: current status |
| Q34368278 | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies |
| Q37965640 | Adjuvant therapy in colon cancer |
| Q36112651 | Advances in Proteomic Technologies and Its Contribution to the Field of Cancer |
| Q47095221 | An integrated lncRNA, microRNA and mRNA signature to improve prognosis prediction of colorectal cancer |
| Q38565991 | Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria |
| Q36196775 | Analysis of whole genomic expression profiles and screening of the key signaling pathways associated with pancreatic cancer |
| Q36016596 | Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer |
| Q85849167 | Aneuploidy and elevated CEA indicate an increased risk for metachronous metastasis in colorectal cancer |
| Q34258176 | Anomalies in network bridges involved in bile Acid metabolism predict outcomes of colorectal cancer patients |
| Q38012676 | Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research |
| Q58053523 | Are Gene Signatures Ready for Use in the Selection of Patients for Adjuvant Treatment? |
| Q33655335 | Associating transcriptional modules with colon cancer survival through weighted gene co-expression network analysis |
| Q41024050 | Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). |
| Q30378787 | Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer. |
| Q53272102 | Association between expression of random gene sets and survival is evident in multiple cancer types and may be explained by sub-classification. |
| Q26744485 | Big Data Analytics for Prostate Radiotherapy |
| Q92159343 | Big Data Approaches for Modeling Response and Resistance to Cancer Drugs |
| Q45284650 | Biological markers: Tailoring treatment and trials to prognosis |
| Q36968539 | Biomarker use in colorectal cancer therapy |
| Q38064740 | Biomarkers in early-stage colorectal cancer: ready for prime time? |
| Q37609130 | Biomarkers in precision therapy in colorectal cancer. |
| Q38259770 | Biomarkers of colorectal cancer: recent advances and future challenges |
| Q36544662 | CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer |
| Q37994133 | Cancer proteomics |
| Q50596135 | Cancer-type OATP1B3 mRNA has the potential to become a detection and prognostic biomarker for human colorectal cancer. |
| Q41565149 | Challenges and strategies for identifying biomarkers for colorectal cancer |
| Q36304759 | Chemotherapy for Stage II Colon Cancer |
| Q60921797 | Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine |
| Q57823440 | Clinical Scoring Systems for Stratifying Risk after Resection of Hepatic Colorectal Metastases: Still Relevant? |
| Q33750119 | Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer |
| Q34473636 | Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. |
| Q58053589 | Clinicopathological risk factors of Stage II colon cancer: results of a prospective study |
| Q36691267 | ColoFinder: a prognostic 9-gene signature improves prognosis for 871 stage II and III colorectal cancer patients |
| Q35740226 | ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients. |
| Q34308855 | Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. |
| Q39184305 | Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models. |
| Q28647615 | Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach |
| Q30238915 | Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer |
| Q37578725 | Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled |
| Q34522228 | Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition |
| Q55411157 | Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. |
| Q47149577 | Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer |
| Q31095892 | Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues |
| Q34692073 | Comparison of prognostic genomic predictors in colorectal cancer. |
| Q46633082 | Comparison of the 7th and 8th editions of the American joint committee on cancer TNM classification for patients with stage III gastric cancer |
| Q53491263 | Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. |
| Q37550749 | Construction and analysis of multiparameter prognostic models for melanoma outcome |
| Q34219117 | Current standards and new trends in the primary treatment of colorectal cancer |
| Q33829763 | Current status of gene expression profiling to assist decision making in stage II colon cancer |
| Q39122119 | DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype |
| Q89481419 | Deep learning for prediction of colorectal cancer outcome: a discovery and validation study |
| Q92668585 | DeepCC: a novel deep learning-based framework for cancer molecular subtype classification |
| Q85428961 | Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases |
| Q36249373 | Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study |
| Q90186768 | Development and validation of a lipogenic genes panel for diagnosis and recurrence of colorectal cancer |
| Q92385622 | Development and validation of an immune-related gene pairs signature in colorectal cancer |
| Q26752713 | Diagnostics based on nucleic acid sequence variant profiling: PCR, hybridization, and NGS approaches |
| Q38484647 | Differential gene expression of the key signalling pathway in para-carcinoma, carcinoma and relapse human pancreatic cancer |
| Q92208614 | Differential gene methylation patterns in cancerous and non‑cancerous cells |
| Q36319754 | Distance in cancer gene expression from stem cells predicts patient survival |
| Q57758061 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making |
| Q39124451 | Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumours |
| Q39395473 | Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples |
| Q35067307 | Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis |
| Q38225744 | Evolving role of gene expression signatures as biomarkers in early-stage colon cancer. |
| Q97539272 | Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges |
| Q34490042 | Exploring gene expression signatures for predicting disease free survival after resection of colorectal cancer liver metastases |
| Q38786707 | From tumour heterogeneity to advances in precision treatment of colorectal cancer |
| Q36247103 | Gene Signatures in Stage II Colon Cancer: A Clinical Review |
| Q26825706 | Gene expression analysis in RA: towards personalized medicine |
| Q28488319 | Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value |
| Q35589710 | Gene expression differences between colon and rectum tumors |
| Q37343279 | Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer |
| Q35742491 | Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. |
| Q47606349 | Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature |
| Q54237552 | Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. |
| Q58598317 | Gene pair based prognostic signature for colorectal colon cancer |
| Q37685157 | Gene profiling and bioinformatics analyses reveal time course differential gene expression in surgically resected colorectal tissues |
| Q35889007 | Gene-expression analysis of a colorectal cancer-specific discriminatory transcript set on formalin-fixed, paraffin-embedded (FFPE) tissue samples |
| Q55058836 | Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer. |
| Q50506281 | Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy. |
| Q41135344 | Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer |
| Q27016019 | Genetic and epigenetic traits as biomarkers in colorectal cancer |
| Q57809354 | Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer |
| Q83389942 | Genetics: an 18-gene signature (ColoPrint®) for colon cancer prognosis |
| Q35550214 | Genistein suppresses FLT4 and inhibits human colorectal cancer metastasis |
| Q26795603 | Genome-wide analysis of microRNA and mRNA expression signatures in cancer |
| Q31012680 | Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? |
| Q35057318 | Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors |
| Q34298860 | Genomics screens for metastasis genes |
| Q90364776 | Glandular orientation and shape determined by computational pathology could identify aggressive tumor for early colon carcinoma: a triple-center study |
| Q45030051 | Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). |
| Q34206403 | High accordance in prognosis prediction of colorectal cancer across independent datasets by multi-gene module expression profiles |
| Q51091655 | High-resolution analysis of DNA copy number alterations in rectal cancer: correlation with metastasis, survival, and mRNA expression. |
| Q34482529 | How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer? |
| Q88139964 | How does genome sequencing impact surgery? |
| Q38630418 | HspB5 correlates with poor prognosis in colorectal cancer and prompts epithelial-mesenchymal transition through ERK signaling. |
| Q92454629 | Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer |
| Q27693248 | Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era |
| Q36512410 | Imaging a functional tumorigenic biomarker in the transformed epithelium |
| Q36485389 | Immunoprofiling for prognostic assessment of colon cancer: a novel complement to ultrastaging |
| Q38703244 | Impact of MLH1 expression on tumor evolution after curative surgical tumor resection in a murine orthotopic xenograft model for human MSI colon cancer |
| Q52989643 | In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. |
| Q64100966 | Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer |
| Q33762117 | Increased platelet-lymphocyte ratio closely relates to inferior clinical features and worse long-term survival in both resected and metastatic colorectal cancer: an updated systematic review and meta-analysis of 24 studies |
| Q34759746 | Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer |
| Q35561695 | Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer |
| Q37537989 | Integrative gene network construction to analyze cancer recurrence using semi-supervised learning |
| Q58053534 | Intrinsic cancer subtypes-next steps into personalized medicine |
| Q35959060 | K-ras genetic mutation and influencing factor analysis for Han and Uygur nationality colorectal cancer patients |
| Q31147888 | Large-Scale Analysis of Gene Expression Data Reveals a Novel Gene Expression Signature Associated with Colorectal Cancer Distant Recurrence |
| Q34356149 | Liquid biopsy: monitoring cancer-genetics in the blood |
| Q26752457 | Long Non-Coding RNAs As Potential Novel Prognostic Biomarkers in Colorectal Cancer |
| Q39180723 | Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. |
| Q24304423 | MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling |
| Q37182264 | Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer |
| Q38652227 | Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer |
| Q93216968 | MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer |
| Q41080927 | Methylation of WNT target genes AXIN2 and DKK1 as robust biomarkers for recurrence prediction in stage II colon cancer |
| Q38947671 | Molecular Diagnostic Applications in Colorectal Cancer. |
| Q26747329 | Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer |
| Q35125605 | Molecular alterations associated with liver metastases development in colorectal cancer patients |
| Q41038524 | Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. |
| Q59794745 | Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream |
| Q38762495 | Molecular evolution of colorectal cancer: from multistep carcinogenesis to the big bang |
| Q42406512 | Molecular genetics of colorectal cancer |
| Q35761956 | Molecular markers predictive of chemotherapy response in colorectal cancer |
| Q33613616 | Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study |
| Q88727587 | Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities |
| Q30581136 | Multiscale integration of -omic, imaging, and clinical data in biomedical informatics |
| Q37109573 | Mutanome and expression of immune response genes in microsatellite stable colon cancer |
| Q40386896 | Mutant-Allele Tumor Heterogeneity Scores Correlate With Risk of Metastases in Colon Cancer. |
| Q35913399 | Myogenic transcription factors regulate pro-metastatic miR-182. |
| Q36619390 | NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models |
| Q34238930 | Next-generation sequencing for cancer diagnostics: a practical perspective. |
| Q58747505 | Novel digital signatures of tissue phenotypes for predicting distant metastasis in colorectal cancer |
| Q28392088 | One-step extrapolation of the prediction performance of a gene signature derived from a small study |
| Q94526774 | Outcomes of Adjuvant Oral versus Intravenous Fluoropyrimidines for High-Risk Stage II or Stage III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study |
| Q60956607 | Overexpression Is Associated With Tumor Progression and Poor Survival in Colorectal Cancer |
| Q37142821 | Overview of personalized medicine in GI cancers |
| Q37701684 | Pan-organ transcriptome variation across 21 cancer types |
| Q38363276 | Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies |
| Q38390834 | Personalized treatment for patients with colorectal cancer: role of biomarkers |
| Q37979676 | Personalized treatment of colorectal cancer |
| Q47111568 | Platform-independent gene expression signature differentiates sessile serrated adenomas/polyps and hyperplastic polyps of the colon. |
| Q30846979 | Policy: EU data protection regulation--harming cancer research |
| Q39166874 | Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions |
| Q38179024 | Precision treatment for cancer: role of prognostic and predictive markers |
| Q58714868 | Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data |
| Q58614422 | Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes |
| Q38555225 | Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon |
| Q89529095 | Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges |
| Q26830362 | Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? |
| Q37960201 | Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer |
| Q28073948 | Prognostic gene expression profiling in esophageal cancer: a systematic review |
| Q37624508 | Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer |
| Q37416261 | Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer |
| Q39021801 | Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients |
| Q91860831 | Promotion of the Warburg effect is associated with poor benefit from adjuvant chemotherapy in colorectal cancer |
| Q57493788 | Proposal for a New TNM Stage based on the 7 and 8 American Joint Committee on Cancer pTNM Staging Classification for Gastric Cancer |
| Q54962725 | Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics. |
| Q30586236 | Quality assessment and data handling methods for Affymetrix Gene 1.0 ST arrays with variable RNA integrity |
| Q37726604 | RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis. |
| Q38041974 | Recent approaches to identifying biomarkers for high-risk stage II colon cancer |
| Q37382559 | Recent progress and clinical importance on pharmacogenetics in cancer therapy. |
| Q37956050 | Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain |
| Q50620413 | Refining prognosis in early-stage colorectal cancer: one or multiple genes at a time? |
| Q47144679 | Regulatory activity based risk model identifies survival of stage II and III colorectal carcinoma |
| Q41621899 | Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients |
| Q42125441 | Risk score based on three mRNA expression predicts the survival of bladder cancer |
| Q35411665 | Semi-supervised learning improves gene expression-based prediction of cancer recurrence |
| Q35653762 | Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer |
| Q38906913 | Stromal contribution to the colorectal cancer transcriptome. |
| Q34526671 | Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines |
| Q59789151 | Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling |
| Q43519619 | Systems oncology: toward the clinical application of cancer systems biology |
| Q39105549 | TGF-β: an emerging player in drug resistance |
| Q41340592 | TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study |
| Q30854540 | Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data |
| Q54693967 | The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients. |
| Q24293460 | The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis |
| Q37445834 | The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes |
| Q37507488 | The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer |
| Q89471675 | The prognostic value of a seven-lncRNA signature in patients with esophageal squamous cell carcinoma: a lncRNA expression analysis |
| Q63883997 | Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy |
| Q54923469 | Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer. |
| Q34519034 | Translating RNA sequencing into clinical diagnostics: opportunities and challenges. |
| Q38779895 | Translating colorectal cancer genetics into clinically useful biomarkers |
| Q38079125 | Translating metastasis-related biomarkers to the clinic--progress and pitfalls |
| Q57524855 | Trends in the characteristics of human functional genomic data on the gene expression omnibus, 2001–2017 |
| Q34441837 | Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update |
| Q51045025 | Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. |
| Q39559509 | Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1. |
| Q51554436 | What can molecular pathology offer for optimal decision making? |
| Q37354154 | hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy |
Search more.